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Abstract
Gram-positive cocci are important causes of infection both in the community and in the hospital, with repercussions on
mortality and increased economic costs. Treatment of these infections is made difficult by the increasing emergence of
multi-resistant organisms, primarily among Gram-positive cocci, such as vancomycin-resistant enterococci, methicillin-resistant
Staphylococcus aureus and coagulase-negative staphylococci, and penicillin-resistant pneumococci. Linezolid, a member of the new
class of synthetic antimicrobials named oxazolidinones, has several favourable characteristics including high activity against
multiresistant Gram-positive cocci. In a number of clinical trials, linezolid showed good clinical and microbiologic efficacy in the
therapy of infections caused by these organisms. It can be considered a valid option for treating both community- and
hospital-acquired infections due to multiresistant Gram-positive cocci. © 2000 Elsevier Science B.V. and International Society of
Chemotherapy. All rights reserved.
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1. Introduction
The last decade has witnessed significant shifts in the
aetiology of nosocomial infections from easily treated
pathogens such as Escherichia coli, Proteus mirabilis,
Klebsiella pneumoniae to more resistant pathogens
(staphylococci, enterococci, Enterobacter spp, Pseu-
domonas aeruginosa, and Candida spp). In general, there
is also a shift from Gram-negative bacilli (GNB) to
gram-positive cocci (GPC) and fungi [1,2]. Thirty nine
percent of nosocomial infections are currently caused
by GPC, and this percentage increases to over 50% in
surgical site infections (SSIs) and bloodstream infec-
tions (BSIs), whereas it has decreased to approximately
25% in urinary tract infections (UTIs) and lower res-
piratory tract infections (LRTIs) Fig. 1 [3].
A further problem associated with the current epi-
demiology of nosocomial infections is the emergence of
resistant and multiresistant GPC such as vancomycin-
resistant enterococci (VRE), methicillin-resistant
Staphylococcus aureus (MRSA) and coagulase-negative
staphylococci (MR–CNS), and also S. aureus with
reduced susceptibility to glycopeptides (GISA). The
problem of penicillin-resistant pneumococci (PRP) as a
cause of severe community-acquired infections should
not be underestimated as well.
Clinically relevant VRE first appeared in the United
States (US) in the early 1990s, where a dramatic in-
crease of VRE prevalence rates from 0.3% in 1989 to
3.2% in 1993 in non-intensive care units (non-ICU) and
from 0.4% to 13.6% in ICUs was reported [4]. This
Fig. 1. Etiology of nosocomial infections: prevalence rates (%) of
groups of organisms [3].
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trend continued in subsequent years, and has reached
15.4% for non-ICU units and 23.2% for ICUs in 1997
[5]. A multicentre study carried out in Europe in 1995,
showed a low incidence of VRE, ranging from 0.6% in
Belgium to 4.2% in Switzerland for vancomycin, and
from 0.6% in Belgium and Italy to 3.5% in Spain for
teicoplanin [6].
MRSA strains emerged in the early 1960s [7] but
have spread worldwide only since the 1980s. A recent
nationwide US study on nosocomial BSIs reported
29.3% of MRSA, with a higher incidence in the Eastern
than in the Western states [8]. A European multicentre
study showed an average prevalence rate of 12.8% of
MRSA, but differs widely between Scandinavian (B
1%) and Mediterranean (\30%) countries [9]. Higher
rates were found in ICU patients; the EPIC study
showed an average rate of 59.6%, with the highest
(81%) reported from Italy [10].
Until recently, S. aureus has been fully susceptible to
the glycopeptides, the first strain with reduced suscepti-
bility to vancomycin isolated in 1996 in Japan [11].
Two other isolates were reported in 1997 from the
US [12]. Strains with reduced susceptibility to tei-
coplanin have been isolated, such that the acronym
GISA (glycopeptide-intermediate S. aureus) has been
proposed. GISA is currently of great concern because
of its potential resistance to all available antimicrobial
agents. The prevalence of MR–CNS is even higher
than that of MRSA. In the US, 65% of CNS isolates
from blood are resistant to methicillin [13], and
in Finland the incidence of methicillin-resistant
Staphylococcus epidermidis (MRSE) increased from
28% in 1983 to 77% in 1994 [14]. Obviously, the preva-
lence of MRSE has increased in the ICU. The EPIC
study showed an average rate of prevalence of 70.1%
[10].
Streptococcus pneumoniae, initially susceptible to
penicillin and other b-lactams as well as other anti-
microbial agents, acquired reduced penicillin suscepti-
bility (MIC0.6 mg:L) in 1967 in Australia [15]. Re-
sistance to multiple antibiotics was reported in 1977
from South Africa [16]. Currently, the prevalence of
PRP in the US, France, Spain, most of Eastern Europe,
Turkey, South Africa, and the Far East is greater than
30%, whereas a lower prevalence (B10%) is found in
North Africa, New Zealand, and some parts of Europe
[17].
The most important consequence of bacterial resis-
tance to antibiotics is the difficulty in treating infections
caused by resistant and multi-resistant organisms. Se-
lection is limited to a few antimicrobials that have a
low therapeutic index or which exert selective pressure
for the emergence of resistance. The prudent use of
antibiotics and the introduction of new potent antimi-
crobials are very desirable.
2. Bacteriologic and pharmacokinetic properties of
linezolid, a new oxazolidinones
Oxazolidinones, a new class of synthetic antimicro-
bials unrelated to any other currently available agents,
were first presented at the 27th Interscience Conference
on Antimicrobial Agents and Chemotherapy in New
York in 1987 [18]. Linezolid, the most studied member,
has a number of favourable characteristics such as a
specific mechanism of action, lack of cross-resistance
with other agents, high oral bioavailability, and a spec-
trum of activity that includes multi-resistant bacteria.
Linezolid has been shown to have high activity against
S. aureus and S. epidermidis, enterococci, and strepto-
cocci [19]. Gram-negative anaerobes and mycobacteria
are generally susceptible as well, whereas Enterobacteri-
aceae and other Gram-negative bacteria are resistant
[20]. Linezolid selectively binds to the 50S subunit near
the interface with the 30S subunit. This results in
distortion that inhibits the formation of the initiation
complex constructed with 30S ribosomes, mRNA, ini-
tiation factors IF2 and IF3, and fMet-tRNA [19,21]. It
does not inhibit the peptide elongation phase, such that
this drug is generally believed to be bacteriostatic.
Concentration-dependent killing has been described for
some species (especially streptococci), while no concen-
tration-dependent killing could be demonstrated for
staphylococci or enterococci [22]. Because of its mecha-
nism of action, linezolid does not exhibit cross-resis-
tance with other groups of antibiotic. Preliminary
studies suggested that spontaneous mutations for resis-
tance among staphylococci rarely occur and that the
appearance of resistant mutants during clinical applica-
tion is unlikely or may occur very slowly [19,23].
Linezolid can be administered both orally and par-
enterally. After oral administration, the maximum peak
plasma concentrations occur within 1–2 h. Linear ki-
netics are seen with both oral and parenteral routes.
The elimination half-life is approximately 5 h and the
protein binding is approximately 31% [19].
Several studies have evaluated the in vitro efficacy of
linezolid against important GPC and compared it with
other antibiotics, such as glycopeptides,
fluoroquinolones, and streptogramins. Against S. au-
reus, linezolid has a MIC90 of 2 mg:L. The MICs
ranged from 0.25 to 2 mg:L for both vancomycin-sus-
ceptible and -resistant enterococci. All streptococci
were inhibited at MICs of 4 mg:L or less [19]. Wise et
al. reported MICs of 0.5–1 mg:L for both methicillin-
susceptible and -resistant S. aureus, S. epidermidis, and
S. saprophyticus, MICs of 0.5–2 mg:L against strepto-
cocci, including penicillin- and fluoroquinolone-resis-
tant S. pneumoniae, and MICs of 0.5–2 mg:L against
anaerobes. Enterococcus faecalis and Enterococcus fae-
cium, including VRE strains (with both 6anA and 6anB)
were uniformly highly susceptible to linezolid [20]. Sim-
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ilar MIC values have been reported by other workers
[21–25]. Von Eiff and Peters found that the in vitro
activity of linezolid was similar to that of glycopeptides
against MRSA, and its antistaphylococcal activity re-
mained almost unchanged, irrespective of the methi-
cillin resistance phenotype [24].
The combination of the pharmacokinetic profile and
post-antibiotic effect (PAE) of linezolid is important in
determining the most appropriate dosing interval. Line-
zolid’s PAE is relatively short. It is greater at four times
MIC (range: 0.2–1.4 h) than at the MIC (0.1–0.8 h)
against all organisms tested, and it is considerably
lower against E. faecalis than against E. faecium and
staphylococci. Based upon preliminary pharmacoki-
netic studies which reported a prolonged serum half-life
(5–6 h), this agent may be given at intervals of 8–12 h
[23].
3. Clinical and microbiologic efficacy and safety profile
of linezolid
In a few phase II clinical trials, linezolid was used at
either low (375 mg bid or 250 mg tid) or high (625 mg
bid or 375 mg tid) doses intravenously. This was fol-
lowed by oral administration for an overall duration
ranging from 5 to 14 days (up to 28 days in bac-
teremias). In patients with community-acquired pneu-
monia, clinical success was obtained in 93% of cases
(87% with low doses and 100% with high doses) and
bacterial eradication in 94% of both pneumococcal and
nonpneumococcal pneumonias. At short-term follow-
up, S. pneumoniae was eradicated in 100% of patients in
both low- and high-dose groups. In subjects with skin
or soft-tissue infections (SSTIs), the rates were 91% for
clinical efficacy (92% with low doses and 89% with high
doses) and 95% for bacterial eradication, which was
obtained for all relevant pathogens. At short-term fol-
low-up, the microbiologic eradication rates were 98%
for the low-dose group and 100% for the high-dose
group [26].
In a clinical trial on patients with various infections
(primarily bacteremias and intra-abdominal infections)
caused by multi-resistant GPC such as VRE, clinical
success was achieved in 17 out of 18 evaluable patients,
and bacterial eradication in all evaluable subjects [27].
In a phase II study on a number of community-ac-
quired infections, primarily SSTIs, treatment with line-
zolid at daily doses ranging from 375 to 625 mg bid
produced clinical and microbiologic success in 90 and
92% of cases, respectively [28].
Despite the reported lack of in vitro bactericidal
activity, Noskin et al. have successfully treated a 23-
year-old neutropenic woman with persistent VRE bac-
teremia with linezolid 600 mg bid iv plus gentamicin 1
mg:kg tid iv. The E. faecium isolate from blood had
high-level resistance to vancomycin and ampicillin and
was resistant to all antimicrobial agents except chlo-
ramphenicol and gentamicin. The MIC for linezolid
was 2 mg:L and especially significant was that the
bacteremia cleared while the patient remained pro-
foundly neutropenic (B100:mm3) [29].
Among adverse events (AEs) observed in clinical
trials with linezolid, headache, nausea, and diarrhoea
predominated (10–15% incidence), while vomiting, in-
somnia, dizziness, asthenia, and phlebitis in the injec-
tion site appeared less frequently (5–10%).
Mild-to-moderate and reversible increases in both hepa-
tocellular and pancreatic enzymes were the main
changes in laboratory parameters, although haemato-
logical changes could be observed during therapy. They
were however minimal when the doses used in the
phase II protocols were administered for the typical
dosing duration of 10–14 days [26].
In a clinical trial with linezolid for compassionate
use, Birmingham et al. reported an overall AE rate of
36.3%; 11.4% of these possibly linezolid-related As
resulted in discontinuation of therapy. The most com-
mon were thrombocytopenia, dermatological reactions,
decreased haemoglobin level, leukopenia, and allergy
[30]. Another phase II study on safety and tolerance of
linezolid reported AEs in 75.6% of patients, but only
32.7% of patients had AEs considered drug-related. No
life-threatening drug-related AEs have been reported
and no clear evidence of mono-amino-oxydase inhibitor
reactions or serious drug interactions have been ob-
served [31].
Linezolid is an important option for treating both
community- and hospital-acquired infections due to
multi-resistant Gram-positive cocci and for reducing
the increasing selective pressure exerted by glycopep-
tides on hospital Gram-positive cocci because of its
clinical and microbiologic efficacy and its safety profile
[24]. It is exciting to be able to offer patients with
serious Gram-positive infection home oral therapy once
they are stabilised, rather than prolonged hospitalisa-
tion or home intravenous infusions. Instituting a se-
quential therapy makes early discharge from hospital or
home treatment possible, with obvious economic
savings.
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